公告 | 一品红丙戊酸钠注射用浓溶液获批上市

Core Viewpoint - Yipinhong Pharmaceutical Group Co., Ltd. has received approval from the National Medical Products Administration for the sodium valproate injection concentrated solution, which is classified as a Category B product under the national medical insurance scheme [1][2]. Group 1 - The sodium valproate injection concentrated solution is registered as a Class 3 chemical drug, which is considered to have passed the consistency evaluation [1][2]. - The approval of this product enhances the company's portfolio in the pharmaceutical market, particularly in the area of medications covered by national insurance [1][2]. - The announcement regarding the registration certificate was made public through an official notice by the company [2][3].